BRAF Mutation Diversity and Impact on Clinical Outcomes in Non-Small Cell Lung Cancer

被引：0
作者：
Lu, K. [1 ]
Shen, J. P. [2 ]
Lopez-Diaz, F. J. [3 ]
Leal, A. [4 ]
Woodward, B. D. [1 ]
Velcheti, V. [4 ]
Riess, J. W. [5 ]
Mansfield, A. S. [6 ]
Salgia, R. [7 ]
Husain, H. [1 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] CEPIMP Genom, Cordoba, Argentina
[4] NYU Langone, New York, NY USA
[5] Univ Calif Davis, Sacramento, CA USA
[6] Mayo Clin, Rochester, MN USA
[7] City Hope Natl Med Ctr, Duarte, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
BRAF; NSCLC; Targeted Therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.12C.01
引用
收藏
页码：S341 / S341
页数：1
相关论文
共 50 条
[41]   Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy [J].
Gu, Guomin ;
Liu, Chunling ;
Zhu, Xiaodan ;
Yang, Yan ;
Song, Shuming ;
Zhao, Yan ;
Sun, Gang .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (09)
[42]   Impact of metformin use on survival outcomes in non-small cell lung cancer treated with platinum [J].
Xin Wen-Xiu ;
Zheng Xiao-Wei ;
Ding Hai-Ying ;
Tong Ying-Hui ;
Kong Si-Si ;
Zhou Xiao-Fang ;
Ping Huang .
MEDICINE, 2018, 97 (51)
[43]   Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC) [J].
Carlson, Josh J. ;
Reyes, Carolina ;
Oestreicher, Nina ;
Lubeck, Deborah ;
Ramsey, Scott D. ;
Veenstra, David L. .
LUNG CANCER, 2008, 61 (03) :405-415
[44]   Clinical Characteristics and Outcomes of EGFRPositive Non-Small Cell Lung Cancer with Acquired RET Fusions [J].
Kobayashi, T. ;
Shinno, Y. ;
Yamaguchi, Y. ;
Matsumoto, Y. ;
Okuma, Y. ;
Yoshida, T. ;
Goto, Y. ;
Horinouchi, H. ;
Yamamoto, N. ;
Ohe, Y. .
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) :S633-S633
[45]   RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies [J].
Giopanou, Ioanna ;
Pintzas, Alexandros .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 146
[46]   Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance [J].
Schwartzberg, Lee S. ;
Horinouchi, Hidehito ;
Chan, David ;
Chernilo, Sara ;
Tsai, Michaela L. ;
Isla, Dolores ;
Escriu, Carles ;
Bennett, John P. ;
Clark-Langone, Kim ;
Svedman, Christer ;
Tomasini, Pascale .
NPJ PRECISION ONCOLOGY, 2020, 4 (01)
[47]   Vemurafenib in Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of the AcSe Trial [J].
Mazieres, Julien ;
Cropet, Claire ;
Barlesi, Fabrice ;
Souquet, Pierre Jean ;
Avrillon, Virginie ;
Coudert, Bruno ;
Le Treut, Jacques ;
Piocelle, Frederique Orsini ;
Quere, Gilles ;
Fabre, Elizabeth ;
Tredaniel, Jean ;
Wislez, Marie ;
Huillard, Olivier ;
Dansin, Eric ;
Moro-Sibilot, Denis ;
Blons, Helene ;
Ferretti, Gilbert ;
Lonchamp, Etienne ;
Labouret, Natalie Hoog ;
Pezzella, Veronica ;
Oukhatar, Celine Mahier Ait ;
Blay, Jean-Yves .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S1182-S1183
[48]   Targeted therapies for non-small cell lung cancer [J].
Papaetis, G. S. ;
Roussos, C. ;
Syrigos, K. N. .
CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (27) :2810-2831
[49]   MEK inhibition in non-small cell lung cancer [J].
Stinchcombe, Thomas E. ;
Johnson, Gary L. .
LUNG CANCER, 2014, 86 (02) :121-125
[50]   Targeted therapies for non-small cell lung cancer [J].
Dempke, Wolfram C. M. ;
Suto, Tamas ;
Reck, Martin .
LUNG CANCER, 2010, 67 (03) :257-274
12345